vBulletin stats
  1. Feel free to join, discuss and list your real estate properties. Never put your hard earned money in real estate without discussing the projects. Please don't throw around your website's link.
  2. Get stock markets trading ideas and strategies. Discuss Personal finance and plan your retirement. Join home buying forum to post your investment and trading questions.
  3. Post your rental queries in the city specific forum. If you are looking for a house, provide additional details like budget & specifications like 1BHK, 2BHK etc. If you are posting about your property for rent, provide maximum information like rent, locality, floor etc.

Free Share Trading Tips- Buy Aurobindo Pharma

Discussion in 'Equity Investment Discussions' started by real_buzz, Dec 23, 2012.

  1. real_buzz Moderator

    Free Share Trading Tips- Buy Aurobindo Pharma

    • Looking beyond concerns: Aurobindo Pharma has been reeling under pressures from various quarters including (1) the US Food and Drug Administration (USFDA) scrutiny on some of its key manufacturing facilities; (2) fluctuation in foreign currency resulting in substantial marked-to-market (MTM) losses; and (3) an enquiry by the Central Bureau of Investigation (CBI) into the promoter's links with former chief minister of Andhra Pradesh, YSR Reddy. However, the situation is normalising now. The USFDA has cleared one of its manufacturing units and the management is awaiting USFDA clearance for another unit (Unit VI) that has already undergone USFDA inspection (a positive outcome could bring in incremental revenues of $25-30 million).

    • Change in strategy to rejuvenate growth: The company envisages several changes in its business strategy to rejuvenate growth. These include (a) reduction of the dependence on partners in the developed markets (the USA and Europe) and focus on self-driven businesses (through wholly owned subsidiaries) to ensure predictable growth; (b) focus on niche segments like controlled substances in the USA; (c) focus on cost control and margin expansion; (d) investments in upgrading manufacturing units to avoid USFDA action in future; and (e) aggressive product filings in different countries.

    • Margins and cash flows to improve going ahead: With the expected increase in the export-led business post-resolution of the USFDA issues, the favourable tilt in the revenue mix is likely to boost the margins, resulting in a relatively much better growth in earnings as compared with revenues. The company has also been able to successfully redeem its outstanding foreign currency convertible bonds (FCCBs) through external commercial borrowings in FY2012 and is well funded to meet its commitment of repaying its long-term debt (close to $80 million) in the current fiscal. Though the net debt level continues to be high (a debt-equity ratio at 1.1x) but we expect the improving operating performance and the consequent strong internal generation of cash flows to ease the stress on the balance sheet (the debt-equity ratio is likely to drop to 0.5x by FY2015E).

    • Available at a discount to its peers; initiate coverage with a Buy call: Though the stock has run up recently, it is still trading at a 30% discount to its long-term average multiple (around 13.5x one-year forward earnings) and at close to an average discount of 20% to some of its peers (like Torrent Pharmaceuticals and Ipca Laboratories) despite the fact that it has a relatively much better product pipeline. Thus, we see scope for substantial re-rating of the stock, in line with a distinct improvement in its financial performance. Consequently, we recommend Buy on the stock with a price target of Rs247 (12x average of FY2014 and FY2015 estimated earnings). Any negative development on the nod from the USFDA or any enquiry related to the promoter's links with the politician is a potential risk to our prognosis.

Share This Page